Unfortunately, the possibility of starting gilteritinib as a pre-emptive strategy only in patients who manifest a minimal residual disease positivity after HSCT (similarly to acute lymphoblastic leukemia Philadelphia-positive [67]) is hampered by technical difficulties to exactly quantify FLT3 mutation [68]. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.